CP
IBRX icon

CenterBook Partners’s ImmunityBio IBRX Stock Holding History

CenterBook Partners’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.34M Buy
+495,942
New +$3.75M 0.21% 119

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CenterBook Partners's IBRX Position: Q2 2026 in Review

CenterBook Partners opened a new position in ImmunityBio (IBRX) in Q2 2026: 495,942 shares worth $4.34M. The stake represents 0.21% of the portfolio and ranks #119 among its holdings.

404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • CenterBook Partners held 495,942 shares of ImmunityBio worth $4.34M as of Q2 2026.
  • ImmunityBio was a new CenterBook Partners position in Q2 2026.
  • ImmunityBio made up 0.21% of CenterBook Partners's portfolio in Q2 2026, its #119 holding.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.